Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) CEO Richard A. Md Miller purchased 10,000 shares of the business’s stock in a transaction dated Monday, November 20th. The stock was purchased at an average price of $10.79 per share, for a total transaction of $107,900.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Corvus Pharmaceuticals, Inc. (NASDAQ CRVS) traded down $0.41 on Wednesday, reaching $10.09. The company had a trading volume of 150,100 shares, compared to its average volume of 108,400. Corvus Pharmaceuticals, Inc. has a fifty-two week low of $8.27 and a fifty-two week high of $22.14.

Corvus Pharmaceuticals (NASDAQ:CRVS) last released its earnings results on Thursday, November 2nd. The company reported ($0.62) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.81) by $0.19. analysts expect that Corvus Pharmaceuticals, Inc. will post -2.82 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Corvus Pharmaceuticals, Inc. (CRVS) CEO Richard A. Md Miller Buys 10,000 Shares” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US & international copyright legislation. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/11/22/corvus-pharmaceuticals-inc-crvs-ceo-richard-a-md-miller-buys-10000-shares.html.

A number of analysts have recently commented on CRVS shares. Zacks Investment Research upgraded Corvus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, October 10th. Wedbush started coverage on Corvus Pharmaceuticals in a report on Wednesday, August 2nd. They set an “outperform” rating and a $26.00 target price on the stock. Finally, Credit Suisse Group upgraded Corvus Pharmaceuticals from an “underperform” rating to a “neutral” rating and set a $14.00 target price on the stock in a report on Wednesday, August 23rd. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $20.25.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Jennison Associates LLC raised its holdings in Corvus Pharmaceuticals by 87.4% during the second quarter. Jennison Associates LLC now owns 1,019,013 shares of the company’s stock worth $12,330,000 after acquiring an additional 475,164 shares in the last quarter. EcoR1 Capital LLC bought a new stake in Corvus Pharmaceuticals during the second quarter worth about $9,741,000. Vanguard Group Inc. increased its position in Corvus Pharmaceuticals by 37.1% during the second quarter. Vanguard Group Inc. now owns 373,512 shares of the company’s stock worth $4,520,000 after buying an additional 101,013 shares during the last quarter. JPMorgan Chase & Co. increased its position in Corvus Pharmaceuticals by 116.0% during the second quarter. JPMorgan Chase & Co. now owns 332,634 shares of the company’s stock worth $4,025,000 after buying an additional 178,658 shares during the last quarter. Finally, Northern Trust Corp increased its position in Corvus Pharmaceuticals by 97.6% during the second quarter. Northern Trust Corp now owns 86,525 shares of the company’s stock worth $1,047,000 after buying an additional 42,739 shares during the last quarter. Institutional investors and hedge funds own 81.61% of the company’s stock.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response.

Receive News & Stock Ratings for Corvus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.